Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.

Official Title

Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.

Brief Summary

      Clinical trial phase IIb, double-blind, randomized, controlled with placebo. There is
      sufficient preliminary evidence to consider intracoronary injection of bone marrow progenitor
      cells as a viable, safe and beneficial treatment in patients with dilated cardiomyopathy,
      although the biological mechanism of action of bone marrow cells in the myocardium is not
      known. In this project we propose to investigate comparatively and from a biological and
      clinical point of view the applicability of regenerative therapy with autologous bone marrow
      cells in patients with dilated cardiomyopathy.

Detailed Description

      The study population correspond to male and female patients with idiopathic dilated

      51 patients diagnosed with this disease are included. After inclusion, will proceed to the
      random allocation to study group or control group in a 2:1 ratio, 34 patients in the
      treatment group and 17 in the control group.

      The total duration is expected to be 48 months: The inclusion period is 24 months and each
      patient assigned to the experimental group will be followed for 24 months, whereas that one
      ramdomized to the control group, will have a folow-up of 12 months. Upon completion there of,
      the patients will be followed in routine clinical practice.

      This is a double blind study, in which all patients will perform the bone marrow harvesting.

      All patients will receive the best medical treatment individualized (ACEIs or Angiotensin II
      receptor blocker, beta-blockers, diuretics and eplerenone) for at least 6 months prior to
      their participation in the clinical trial, so that the situation is stable and
      pharmacological basal condition is the same for everyone.

      The bone marrow cells of patients assigned to placebo group will be cryopreserved, and once
      the trial is completed, the blind will be opened and all the patients who had been randomized
      to the control group, may be processed by the route of compassionate use with their own
      mononuclear bone marrow cells previously frozen.

      The patients who are randomized to experimental group will be treated by the conventional
      treatment + infusion of autologous mononuclear bone marrow cells not expanded whereas the
      patients who are randomized to control group will be treated by the conventional treatment +
      infusion of placebo.

      The main objective is to assess comparative the efficacy of intracoronary injection of bone
      marrow stem cells autologous to improve ventricular function in patients with idiopathic
      dilated cardiomyopathy who receive conventional medical treatment, compared with a control
      group who receive a infusion of placebo and conventional medical treatment. The improvement
      in ventricular function assessed by changes in angiographically determined ejection fraction.

      Secondary objectives of the study are:

      - To analyze the predictors of good clinical response, functional and biological treatment
      with adult stem cells autologous mononuclear bone marrow not expanded in terms of functional

      The following parameters were evaluated: Functional class (NYHA), Natriuretic peptide B,
      Stress test (exercise time), Echocardiographic parameters of ventricular function, for
      example LVEF (%), TDV (ml), TSV (ml) and TAPSE (ms) and Biological parameters of cellular
      functionality, for example CD133 +, CD34 +, CD34 +/CD177 + and CD34 +/CD38- (in %).

      - To determine, in the light of the obtained results, the application protocol suitable cell
      therapy for the treatment of dilated cardiomyopathy.

Study Phase

Phase 2

Study Type


Primary Outcome

Changes in ventricular function measured angiographically.

Secondary Outcome

 Degree of clinical improvement based on the absence of major cardiac events (MACE) during follow-up.


Idiopathic Dilated Cardiomyopathy


Infusion of autologous mononuclear bone marrow cells

Study Arms / Comparison Groups

 Infusion of autologous mononuclear bone marrow cells
Description:  Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 6, 2014

Completion Date

April 21, 2020

Primary Completion Date

October 19, 2018

Eligibility Criteria

        Inclusion Criteria:

          1. Patients of both sexes and ages between 18 and 70 years.

          2. Patients diagnosed with dilated cardiomyopathy established by echocardiography.

          3. Minimum evolution since diagnosis of 6 months.

          4. Absence of coronary injury tested with multislice CT and/or hemodynamic study
             performed after study entry, or within the previous 36 months (or before in specific
             low risk clinical profiles) if no angina symptomatology is present.

          5. Patients receiving optimized medical therapy for at least 6 months prior to enrollment
             (individually adjusted according to functional status).

          6. Ejection fraction of the left ventricle <40% or ejection fraction of the left
             ventricle 40% -50% if left ventricular tele-diastolic volume is > 110 ml/m2.

          7. Presence of sinus rhythm.

          8. Writen informed consent for participation in the trial.

          9. Normal laboratory parameters, defined by: Leukocytes ≥ 3000; Neutrophils ≥ 1500;
             Platelets ≥ 100,000; Aspartate aminotransferase / Alanine aminotransferase ≤ 2.5
             standard range institution; Creatinine ≤ 2.5 mg / dL; Haemoglobin > 9 g/dL

         10. Women of childbearing potential must have negative results on a pregnancy test and
             agree to use medically approved methods of contraception thoughout follow up.

        Exclusion Criteria:

          1. Secondary Dilated cardiomyopathy.

          2. Recent history of myocarditis (< 6 months prior to study entry).

          3. Patients amenable to receive cardiac resynchronization therapy

          4. Patients in active waiting list for heart transplantation.

          5. Coexistence of other serious systemic diseases.

          6. Coexistence of any type of blood disease

          7. Pregnant or breastfeeding women; or women of childbearing potential not comminting to
             use effective contraception.

          8. Patients who are currently participating, or have completed their participation in a
             clinical trial within the last 3 months. Patients who have participated in any
             advanced therapies clinical trial any time previously.

          9. Patients with malignant or pre-malignant tumors.

         10. Positive serology for hepatitis B virus, hepatitis C virus or human immunodeficiency

         11. Use of any protocolo prohibited medication. A wash-out period of 2 months can be
             considered for inclusion in the trial.




18 Years - 70 Years

Accepts Healthy Volunteers



Miguel Romero Moreno, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud


 Iniciativa Andaluza en Terapias Avanzadas

Study Sponsor

Miguel Romero Moreno, MD, PhD, Principal Investigator, Hospital Universitario Reina Sofía

Verification Date

September 2020